Close

Junk DNA Could Be The Key To Understanding Neuro Ailments

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

BioNTech and Gilead Partner for Pumitamig Clinical Trial

BioNTech SE has officially entered into a clinical trial...

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Cencora has signed a definitive agreement to acquire American...

Merck Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA has entered into an agreement to acquire...
- Advertisement -

According to recent studies, there is a connection between non-coding DNA and some neurological diseases such as Alzheimer’s and motor neurone disease.

Researchers from the Universities of Sheffield and Lincoln studied how oxidative breaks in so-called junk DNA are created and repaired in order to determine whether or not doing so can one day shield humans against neurological illnesses. The revelation opens the door to ground-breaking new research into this junk DNA, which accounts for 98% of all the DNA in human cells.

This is the result of a half-decade of rigorous research by an exceptionally gifted team led by Professor Sherif El-Khamisy at the University of Sheffield, according to lead author and senior lecturer in cell biology at the School of Life and Environmental Sciences at the University of Lincoln, Dr. Swagat Ray.

Oxidative stress is a natural byproduct of cellular metabolism and is influenced by a variety of variables, including the environment, diet, and lifestyle. Long-term oxidative stress can harm the body’s cells, proteins, and DNA irreparably, speeding up ageing and promoting the growth of brain illnesses like dementia, the researcher continued.

Neurological disorders, including motor neurone disease and Alzheimer’s, which are brought on by the progressive death of brain cells called neurons, affect up to a billion individuals worldwide.

The results of this study can now open the door for further investigation that may result in the earlier detection, postponement, or even cure of numerous neurological illnesses.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

BioNTech and Gilead Partner for Pumitamig Clinical Trial

BioNTech SE has officially entered into a clinical trial...

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Cencora has signed a definitive agreement to acquire American...

Merck Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA has entered into an agreement to acquire...

5 Functional Medicine Clinics in Denver for a Personalized Approach to Chronic Inflammation

Chronic inflammation underlies a surprisingly wide range of diagnoses:...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »